Hologic Inc.
Hologic Announces Preliminary Revenue Results for Q1 FY2025
Summary
Hologic, Inc. announced preliminary revenue results for its first fiscal quarter ended December 28, 2024, with total revenues of approximately $1,021.8 million, an increase of 0.9% compared to the prior year period. The increase was 1.0% on a constant currency basis, in line with guidance. The Company expects GAAP and non-GAAP earnings per share to be near the high end of the guidance ranges provided on November 4, 2024. Full financial results will be reported on February 5, 2025.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement